Development of N-Terminally Modified Variants of the CXCR4-Antagonistic Peptide EPI-X4 for Enhanced Plasma Stability

[Image: see text] EPI-X4, a natural peptide CXCR4 antagonist, shows potential for treating inflammation and cancer, but its short plasma stability limits its clinical application. We aimed to improve the plasma stability of EPI-X4 analogues without compromising CXCR4 antagonism. Our findings reveale...

Descripción completa

Detalles Bibliográficos
Autores principales: Harms, Mirja, Fabech Hansson, Rikke, Gilg, Andrea, Almeida-Hernández, Yasser, Löffler, Jessica, Rodríguez-Alfonso, Armando, Habib, Monica M. W., Albers, Dan, Ahmed, Nermin S., Abadi, Ashraf H., Winter, Gordon, Rasche, Volker, Beer, Ambros J., Weidinger, Gilbert, Preising, Nico, Ständker, Ludger, Wiese, Sebastian, Sanchez-Garcia, Elsa, Zelikin, Alexander N., Münch, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682998/
https://www.ncbi.nlm.nih.gov/pubmed/37940118
http://dx.doi.org/10.1021/acs.jmedchem.3c01128

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682998/
https://www.ncbi.nlm.nih.gov/pubmed/37940118
http://dx.doi.org/10.1021/acs.jmedchem.3c01128

Ejemplares similares